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Phenotypic variability in a family 
with x-linked adrenoleukodystrophy 
caused by the p.Trp132Ter mutation
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SUMMARY
X-linked adrenoleukodystrophy (X-ALD) is an inherited disease with clinical heterogeneity 
varying from presymptomatic individuals to rapidly progressive cerebral ALD forms. This disea-
se is characterized by increased concentration of very long chain fatty acids (VLCFAs) in plasma 
and in adrenal, testicular and nervous tissues. Affected individuals can be classified in different 
clinical settings, according to phenotypic expression and age at onset of initial symptoms. Mo-
lecular defects in X-ALD individuals usually result from ABCD1 gene mutations. In the present 
report we describe clinical data and the ABCD1 gene study in two boys affected with the chil-
dhood cerebral form that presented with different symptomatic manifestations at diagnosis. In 
addition, their maternal grandfather had been diagnosed with Addison’s disease indicating phe-
notypic variation for X-ALD within this family. The mutation p.Trp132Ter was identified in both 
male patients; additionally, three females, out of eleven family members, were found to be he-
terozygous after screening for this mutation. In the present report, the molecular analysis was 
especially important since one of the heterozygous females was in first stages of pregnancy. 
Therefore, depending on the fetus outcome, if male and p.Trp132Ter carrier, storage of the um-
bilical cord blood should be recommended as hematopoietic stem cell transplantation could be 
considered as an option for treatment in the future. Arq Bras Endocrinol Metab. 2010;54(8):738-43
SUMÁRIO
A adrenoleucodistrofia é uma doença genética com padrão de herança ligado ao X (X-ALD) 
que apresenta heterogeneidade clínica e varia desde a forma infantil cerebral severa até casos 
de indivíduos pré-sintomáticos. Essa doença é caracterizada pelo acúmulo de ácidos graxos 
de cadeia muito longa (VLCFA) no plasma, nas adrenais, nos testículos e no sistema nervoso. 
Indivíduos afetados podem apresentar diferentes formas clínicas, as quais são classificadas de 
acordo com a expressão fenotípica e a idade de aparecimento dos sintomas iniciais. Alterações 
moleculares em indivíduos com X-ALD são geralmente mutações no gene ABCD1. No presente 
trabalho, descrevemos os dados clínicos e a investigação molecular do gene ABCD1 em uma 
família com duas crianças do sexo masculino afetadas com a forma infantil cerebral, que apre-
sentaram diferenças nas primeiras manifestações sintomáticas para o diagnóstico. Além disso, 
houve referência ao avô materno diagnosticado com doença de Addison’s, indicando a varia-
bilidade fenotípica da X-ALD nessa família. A análise molecular indicou a mutação p.Trp132Ter 
nos dois pacientes masculinos, e três indivíduos do sexo feminino, entre os onze estudados, 
mostraram-se heterozigotos para mutação. O conhecimento molecular descrito no presente 
relato adquiriu maior importância uma vez que uma das portadoras da mutação apresentou-se 
nos primeiros estágios de gestação. Assim, poderá ser oferecida a possibilidade de armazena-
mento de sangue de cordão umbilical para que se possa considerar, no futuro, o transplante de 
células-tronco hematopoiéticas como forma de tratamento, caso a criança seja do sexo mascu-
lino e afetada. Arq Bras Endocrinol Metab. 2010;54(8):738-43
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IntROdUctIOn
Adrenoleukodystrophy (X-ALD - MIM ID #300100) is an inherited X-linked disease charac-
terized by increased concentration of very long chain 
fatty acids (VLCFAs) in plasma that affects myelin, spi-
nal cord, peripheral nerves, adrenal cortex and testis. 
The accumulation of VLCFA may also be observed 
in neonatal ALD, which is considered to be inherited 
as an autosomal recessive disorder. The incidence of 
X-ALD is estimated in 1:20.000 without differences 
among ethnic groups (1). 
Affected individuals may present with different clini-
cal forms that are classified according to phenotypic ex-
pression and age at initial symptoms (Table 1). When 
symptoms are observed before 10 years of age it is char-
acterized as the childhood cerebral form. It manifests as 
progressive neurological damage with rapid evolution, 
leading to a vegetative state within six months to two 
years after onset of symptoms, followed by death at vari-
able ages. The second form is the adrenomyeloneuropa-
thy (AMN), which presents initial symptoms in adult 
men with ages ranging from 20 years to middle-aged 
men. Affected individuals develop progressive weakness 
in the legs, sphincter control abnormalities, and may also 
have serious cognitive and behavioral disturbances over 
the decades. A third variant is the cerebral AMN form 
that presents similar neurological findings in association 
with some other characteristics such as dementia or psy-
chosis. These symptoms arise between 10 and 21 years 
of age denoting a delayed onset with slow evolution 
rates. The fourth form that can be distinguished is Ad-
dison’s disease, which accounts for only 10% of affected 
individuals. In this case, initial signs appear at different 
ages between two years of age and adulthood (1,2). Ad-
ditionally, asymptomatic forms have been identified in 
older men (3). Although it is an X-linked disease, 50% 
of female carriers may develop AMN signals manifesting 
as mild to moderate spastic paraparesis in middle-aged 
women or later with normal adrenal function (4). 
X-ALD is caused by mutations in the ATP-binding 
cassette, subfamily D, member 1 gene (ABCD1 – MIM 
ID *300371). ABCD1 gene is located at Xq28 and 
encodes a peroxisomal adenosin triphosphate (ATP) – 
binding cassette transporter protein (ABCD1, ALDP) 
that plays a crucial role in VLCFA transport, or their 
coenyme A (CoA) derivatives into peroxisomes (5,6). If 
the protein function is impaired no beta oxidation of VL-
CFAs occurs and they accumulate in body fluids and tis-
sues leading either to neuroinflammation and demyelin-
ation in the brain characterizing the cerebral childhood 
form or to axonal degeneration in spinal cord in AMN 
(7). The mechanisms of the disease pathogenesis remain 
unclear whereas it is possible that VLCFA cytotoxicity 
causes oxidative stress with subsequent neuroinflamma-
tion followed by generalized peroximal dysfunction (8).
Neither VLCFA plasma concentration nor the 
type of mutation can usually predict the phenotype 
of X-ALD because a same ABCD1 gene mutation can 
be associated with different phenotypes (9-12). 
The present study reports the phenotypic variabil-
ity and the molecular investigation in a family with 
two affected male cousins with X-linked adrenoleu-
kodystrophy. The ABCD1 gene sequencing indicated 
p.Trp132Ter  mutation segregation in affected male 
individuals and in normal female carriers. 
SUBJEctS And MEtHOdS
clinical data 
Case 1 is a previously healthy boy who presented the 
first symptoms at the age of 6 years. For the last eight 
table 1. X-ALD phenotypes
Phenotypes clinical manifestations
Age at first 
symptoms Frequency
Males
Childhood 
cerebral form
Behavior changes, 
school failure, 
dementia, psychoses, 
paralysis, epilepsy, loss 
of vision, loss of speech
Before 10 years ~ 35%
AMN Paraparesis, sphincter 
disturbances, sensory 
changes, loss of 
coordination, pain, 
impotence
Between 2nd and 
4th decades
~ 40% to 
45%
Addison’s 
disease only
Adrenocortical 
insufficiency
Between 2 years 
and adulthood
~ 10%
AMN cerebral Pure AMN plus 
dementia-like 
behavioral disturbances, 
psychosis, epilepsy, 
aphasia, visual loss
Between 10 and 
21 years
~ 5 to 10%
Asymptomatic None Older than 60 
years
Increasing
Females 
Asymptomatic None Any age ~ 50%
Symptomatic 
carriers
AMN (paraparesis) like 
with normal adrenal 
function
Middle-aged or 
later
~ 50%
Co
py
rig
ht
©
 A
BE
&
M
 to
do
s o
s d
ire
ito
s r
es
er
va
do
s.
740 Arq Bras Endocrinol Metab. 2010;54/8
Phenotypic variability for ABCD1 mutation
months he has manifested vomiting and hyponatrae-
mia once a week. These episodes were followed by 
pronounced dehydration and hypoglycemia. Mild dif-
ficulty in speech and some hyperactivity were observed. 
Family history reported that two members of his ma-
ternal family had deceased without a defined diagnosis: 
his grandfather, who died at the age of 44 years, had 
suffered recurrent episodes of fainting and presented 
clinical data suggestive of Addison’s disease; and, a 
cousin, who started with neurological deficits at the 
age of 17 years, developed into total disability and died 
when he was 21 years old, after a period of vegetative 
life (Figure 1A). Hormonal dosages for Case 1 showed 
high ACTH levels (Table 2); therefore glucocorticoid 
replacement therapy was initiated for adrenal insuffi-
ciency. His neurological abilities have worsened with 
progressive impairment of cognition and behavior. A 
brain magnetic resonance imaging (MRI) exam re-
vealed ventricular asymmetry on the right side with an 
enhanced T-2 signal. He is now 7 years old, presents 
generalized hypotonia, difficulties in understanding 
spoken language, and hearing deficit.
Case 2 is a previously healthy boy with excellent 
performance at school, who was 8 years old when he 
started with attention deficit disorder, last year. Four 
months after that, he manifested difficulties in dressing 
and walking. Rapidly, he presented loss of vision and 
hearing. Treatment with Lorenzo’s oil was introduced 
after signs of X-ALD had been observed in brain MRI. 
Laboratorial evaluation revealed high ACTH level (Ta-
ble 2), therefore glucocorticoid and mineralocorticoid 
replacement therapies were initiated, even before clini-
cal signs of adrenal insufficiency could be observed. He 
is now 9.6 years old and lives in a vegetative state.
table 2. Laboratorial adrenal evaluation at diagnosis.
Method case 1 case 2
Na+ (mmol/L) ISE1 111 137
K+ (mmol/L) ISE1 6.1 4.9
ACTH (pg/mL) EIA - CL2 516 2322
Basal cortisol (mg/dL) EIA - CL3 12.2 5.86
Plasmatic renin activity (pg/mL) IRMA4 17.7 > 520
1 Ion selective electrode; 2 Chemiluminescence Enzyme Immunoassay − normal range up to 46 
pg/mL; 3 Electrochemiluminescence Enzyme Immunoassay − normal range 2.5 to 12.5 mg/dL; 
4 Immunoradiometric assay – normal range 2.4 to 21.6 pg/mL.
Figure 1. (A) X-ALD family pedigree. Twelve family members were molecularly evaluated; arrows indicate index cases. Individuals II.2, II.5, II.8, II.10 and 
II.11 are obligate carriers. Asterisks denote individuals that were personally examined. E+(p.W132Ter) and E-(p.W132Ter) indicate that the individuals have 
been molecularly evaluated for the mutation and are either affected (males) or carriers (females) and normal, respectively. Individuals I.1 and III.6 have not 
been studied however clinical history indicated that they were X-ALD affected individuals. (B-d) Electropherograms for exon 1 ABCD1 gene partial nucleotide 
sequence: DNA sequence with the G>A nucleotide change forming a TGA stop codon, the arrow indicates position of the nucleotide change. (c) heterozygosis 
for G>A nucleotide change observed in three females; (d) ABCD1 sequence denoting the normal TGG codon for tryptophan in residue 132.
Molecular analysis
This study was approved by the Ethics Committee of 
the Universidade Estadual de Campinas (São Paulo, 
Brazil) and informed consents from family members 
were obtained.
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Genomic DNA from peripheral leukocytes was puri-
fied by proteinase K lysis, phenol/chloroform extraction 
and ethanol precipitation using standard techniques 
(13). Each exon of the ABCD1 gene and its respective 
flanking regions were amplified by PCR from genomic 
DNA using primers designed with GeneRunner v3.1 
free software (Table 3). PCR products were purified in 
1% agarose gel electrophoresis with the Wizard SV Gel 
& PCR clean-up system (Promega, USA), and both 
sense and antisense strands were sequenced with the 
BigDye Terminator v3.1 Cycle Sequencing Kit (Ap-
plied Biosystems, USA) using the same primers as for 
the PCR reactions. Chromas Lite and CLC Sequence 
Viewer v.5.0.1 free softwares were used to analyze and 
compare sequences with the reference ABCD1 gene se-
quence (ENSG00000101986, www.ensembl.org).
exon 1 (Figure 1B, C, D). This change creates a stop 
codon at residue 132 and causes the nonsense mutation 
p.Trp132Ter. The screening for p.Trp132Ter mutation 
in the family revealed three heterozygous females out 
of eleven evaluated members (Figure 1A).
dIScUSSIOn
The present report describes a family with two boys af-
fected by X-linked adrenoleukodystrophy. The study of 
the ABCD1 gene revealed mutation p.Trp132Ter as re-
sponsible for the disease. Three female members of the 
family were found to carry the mutation including the 
pregnant sister of the index case. This nonsense muta-
tion was previously described in a patient with child-
hood cerebral adrenoleukodystrophy (11) additionally, 
the X-ALD Mutation Database (http://www.x-ald.nl/
mutations-gene/mutations-in-abcd1) refers to three 
other unpublished cases with the p.Trp132Ter muta-
tion. There are 1,133 mutations annotated for ABCD1 
gene in the Mutation Database last updated on No-
vember 12th, 2010 and almost 50% are recurrent. Ac-
cording to database’s statistics 10% of total mutations 
are nonsense, 22% are frameshift, 61% are missense, 
and the other 7% correspond to insertions or dele-
tions. There are some residues in ALDP that seem to 
be more susceptible to mutations since the same muta-
tion or different mutations in the same amino acid have 
been described in different studies (Figure 2). How-
ever, they do not represent mutation hotspots since 
they occur in almost every exon, except in exons 2, 4 
and 10. Although expression and functional studies for 
p.Trp132Ter mutation have not been performed, it is 
putatively considered to result in the absence of ALDP 
likewise 74% of all mutations identified in ABCD1 gene. 
The two patients described here as carrying the 
same mutation, present the childhood cerebral form 
of the disease although Case 1 has presented clini-
cal signs of adrenal insufficiency more evidently than 
Case 2. It is well known that more than one clinical 
phenotype can manifest within a single X-ALD pedi-
gree (9,10,12). Mild phenotypes have been described 
for some frameshift and nonsense mutations which 
are generally predicted to form a truncated transcript 
(12,14). This variability suggests that the X-linked ad-
renoleukodystrophy phenotype may be influenced to a 
great extent by other genetic or environmental factors 
(8,11). As the family investigation progressed the in-
formation that the maternal grandfather presented Ad-
table 3. Primers designed for amplification and sequencing of ABCD1 
gene
Primer Sequence (5’-3’) Ta (°C)1 Size (bp)
2
5’UTRs GGAGAAGGTGGAGAGGAAGAGA 62.2 1356
Int1as GGCCTGCCCACACCTTTG 62.9
Ex1s3 GGAGACGGGGCTGCTGGC 67.0
Ex1as3 CGACAGGAAGGTGCGGCTC 65.0
Int1s CAGCGTGTGTGAGTGGCA 57.2 717
Int2as GGCTTCCCACTCCTCTAAA 55.7
Int2s GCAGAAGAGCCTCGCCT 56.6 621
Int4as CAGAAGCACATGGAGGTCC 56.5
Int4s GACCTGGCTGTGTTCCCTAG 58.4 483
Int5as CCTTGGTCAATCCTGGTATCA 58.9
Int5s GAGATCAAGAATGGCCTGC 56.3  931
Int7as CCCTTCCCTAGAGCACCTG 58.4
Int7s GCACGATTCCAGTCCCCAC 61.7 1077
3’UTRas CGCCACCCTCCACATCTACT 61.2
Ex9s3 CTGCTCTCCATCACCCACCG 64.7
Int9as3 CAGGCAGGGAGACAGGGC 61.8
1 Anealing temperature used in PCR; 2 Size of amplified fragments; 3 Internal primers used for 
sequencing only.
RESULtS
Clinical and laboratorial data indicated that in Case 1, the 
initial presentation was adrenal insufficiency followed by 
mild to moderated neurological manifestations, whereas 
in Case 2 neurological damage was the first sign that 
evolved rapidly and drastically to a severe condition with-
out clinical indicatives of adrenal insufficiency.
ABCD1 sequence analysis of the affected individu-
als revealed the nucleotide change TGG>TGA within 
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Figure 2. Schematic representation of the 10 exons of ABCD1 gene. Amino acid residues at which more than ten cases have been reported with different 
mutations are denoted. Numbers of reported cases are in parenthesis. The mutation described in this report is represented in bold.
dison’s disease was obtained. Considering that he prob-
ably carried the mutation, it can be inferred there is a 
second clinical form for p.Trp132Ter within the family. 
These data confirm phenotypic variability for ABCD1 
gene mutations already reported by others (11,12,15) 
and suggest that modifier genes or environmental/epi-
genetic/stochastic factors might modulate the clinical 
outcome of the disease (8). 
As the X-ALD diagnosis is established, steroid re-
placement therapy is mandatory to prevent the con-
sequences of adrenocortical insufficiency and may be 
life saving, but it does not alter the rate of neurologic 
progression (2,16). In fact, there is no correlation be-
tween adrenal involvement and the type of neurologic 
involvement or the rate of neurologic progression (14). 
In order to impair the neuroinflammatory demyelinat-
ing process of X-ALD, hematopoietic stem cell trans-
plantation (HSCT) can be performed at early stages of 
the disease (17,18), before manifestation of any signifi-
cant neurologic deficits, when limited extensions of the 
lesion can be observed upon brain MRI (19). In fact, 
HSCT is mostly limited to patients at the stage of initial 
signs of Addison’s disease or those asymptomatic indi-
viduals within a family who have been  identified during 
genetic counseling (1,20). Actually, HSCT is mostly 
recommended for AMN patients with cerebral involve-
ment (19). There are two other treatments available for 
patients with X-ALD: corticosteroid replacement ther-
apy, indicated for Addison’s disease, and Lorenzo’s oil 
therapy. Lorenzo’s oil is a 4:1 mixture of glyceryl-trio-
leate and glyceryl-trierucate, which normalizes plasma 
VLCFA levels in X-ALD patients but does not impair 
progression of cerebral lesion (2). Its clinical efficacy 
and the clinical indications for its use are still controver-
sial (20). Novel therapies have been tentatively tested. 
Recent trials have shown that neither immunosuppres-
sive/immunomodulating therapies nor lovastatin treat-
ment were useful for patients with cerebral damage. 
Antioxidative treatments could possibly be a future 
therapeutic option as they are considered to have some 
neuroprotective effect (19,21). Nevertheless, molecu-
lar testing is an important tool to have in hands since it 
contributes not only for diagnosis, especially when the 
analysis of VLCFAs in plasma is not available, but also 
for genetic counseling purposes as in the family here 
described. In addition, when an ABCD1 mutation is 
identified in asymptomatic affected males they might 
be candidates for HSCT to prevent neurodegenerative 
processes (17,18). 
Finally, analysis of the ABCD1 gene in women with-
in an affected family can provide information about the 
origin of the disease but, most important, is that it pro-
vides the possibility of evaluating the risk of transmis-
sion because of the X-linked maternal inheritance of 
the disease (11). In the present family, individual III.1 
that was found to be heterozygous for the p.Trp132Ter 
mutation is at the first stages of pregnancy. Conse-
quently, depending on the fetus outcome, if male and 
p.Trp132Ter  carrier, the umbilical cord blood storage 
should be recommended as HSCT could be considered 
in the future.
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